Clinical research on the improving effect of the glucose metabolism and vascular endothelial function by piceatannol

Clinical research on the improving effect of the glucose metabolism and vascular endothelial function by piceatannol - Piceatannol 2

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000018397

Enrollment

Registered

2015-07-23

Start date

2015-06-29

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy subject and healthy subject with obesity

Interventions

Piceatannol(Group) Taking 4cap/day, twice a day before 30min of breakfast and dinner Taking piceatannol during 2months Placebo(Group) Taking 4cap/day, twice a day before 30min of breakfast and din

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1)Group of Healthy subjects(>=20years old and <70years old): BMI >=18.5 and <25, individuals who have no abnormalities on glucose tolerance, lipid profile and liver function, which are referred by the results of medical examination within one year (When there is no medical examination result within one year, subject needs to take the blood sampling inspection.) (2)Group of healthy subjects with obesity(>=20years old and <70years old): BMI>=25 or visceral fat area>=100cm2, and individuals who have no medication. (3)Individual who has the ability of consent and can sign a written informed consent

Exclusion criteria

Exclusion criteria: (1)Women who are pregnant, or possibility of pregnant, or wish to pregnant, or lactating. (2)Individual who has a smoking habit. (3)Individual who has a history of allergy to piceatannol (4)Individual who has a food allergy. (5)Participants who are considered unsuitable for inclusion by the attending physician.

Design outcomes

Primary

Measure	Time frame
* Glucose metabolism: blood glucose, insulin, HbA1c, glycated-albumin * Endothelial function: FMD, ADMA, high sensitivity-CRP	—

Secondary

Measure	Time frame
* Body weight, BMI, amount of body fat, % of body fat, skeletal muscle mass, visceral fat area, (In body) * Changing of the expression and activity of SIRT1 and AMPK on isolated peripheral blood mononuclear cells * Lipid metabolism: TC, HDL-C, TG, LDL-C, FFA * Inflammation: IL-6 * Fatigue: d-ROM, BAP, VAS test (Japan Society of fatigue Science, supervision) * Metabolites of piceatannol in blood and urine * Urinary albumin and creatinine * POMS(Mood profile test, questionnaire method) * Safety of throughout the entire study period	—

Measure

Time frame

* Body weight, BMI, amount of body fat, % of body fat, skeletal muscle mass, visceral fat area, (In body) * Changing of the expression and activity of SIRT1 and AMPK on isolated peripheral blood mononuclear cells * Lipid metabolism: TC, HDL-C, TG, LDL-C, FFA * Inflammation: IL-6 * Fatigue: d-ROM, BAP, VAS test (Japan Society of fatigue Science, supervision) * Metabolites of piceatannol in blood and urine * Urinary albumin and creatinine * POMS(Mood profile test, questionnaire method) * Safety of throughout the entire study period

—

Countries

Japan

Contacts

Public ContactYuka Kuroshima

Kanazawa Medical University Daibetology & Endocrinology

naipicrc@kanazawa-med.ac.jp076-286-2211

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026